DEFA14A: TransCode Therapeutics Seeks Shareholder Approval for Reverse Stock Split to Maintain NASDAQ Listing

TransCode Therapeutics is asking shareholders to vote in favor of a reverse stock split at a special meeting on April 21st to maintain its NASDAQ listing and facilitate future capital raising.

Summary

• TransCode Therapeutics is seeking shareholder approval for a reverse stock split to maintain its NASDAQ listing.
• The company believes maintaining the listing is crucial for future capital raising.
• They need to achieve a closing bid price of $1.00 or above by May 5, 2025, to avoid delisting.
• The company has secured approximately $18M in recent financings, which is expected to fund operations into the fourth quarter of 2025.
• Additional capital will be needed beyond the fourth quarter of 2025.
• The company received a $2M grant from the NIH in 2024 and is pursuing additional non-dilutive funding and partnerships.
• Shareholders are asked to vote by 11:59 pm ET on April 20, 2025.
• The board does not intend to effect the split even if it has been approved, should the stock close above $1.00 in the timeframe required and continues trading above $1.00.

Sentiment

Score: 5

Explanation: The document conveys a mixed sentiment. While the company has secured funding and is progressing with its clinical trial, it faces the risk of delisting and needs to undertake a reverse stock split, which is generally viewed negatively. The management expresses optimism but acknowledges the challenges.

Positives

• TransCode Therapeutics has secured approximately $18M in recent financings.
• The company's clinical program for TTX-MC138 is progressing as planned and is well into its fourth dosing cohort.
• The company received a $2M grant from the NIH in 2024.
• The company is actively pursuing non-dilutive funding and partnerships.
• The company has extended its cash runway to continue to pursue its most significant and potentially valuable milestones, including further clinical development progress with its lead therapeutic candidate.

Negatives

• TransCode Therapeutics' share price is below the NASDAQ minimum of $1.00.
• The company risks losing its NASDAQ listing if it does not achieve a $1.00 share price by May 5, 2025.
• The company will require additional capital beyond the fourth quarter of 2025.
• Raising additional capital is expected to be challenging.

Risks

• The company's ability to maintain its NASDAQ listing is uncertain.
• The company's ability to secure additional financing on acceptable terms is not guaranteed.
• Clinical trial outcomes may not be positive.
• The company may not receive grant funding or partnership agreements.
• The company's dependence on third parties poses a risk.
• The company's ability to continue as a going concern is dependent on obtaining additional funding.

Future Outlook

The company anticipates needing additional capital beyond the fourth quarter of 2025 and is pursuing various funding options, including non-dilutive grants and partnerships, while advancing its clinical trial program.

Management Comments

• The Board of Directors and management unanimously believe that maintaining our Nasdaq listing is critical to the future of our company.
• We believe that the reverse split approval is essential to enable us to remain listed with NASDAQ, giving us a better chance of raising the additional capital we will need to continue to advance our clinical trial program.
• We assure you that we do everything we possibly can to minimize the cost of obtaining the capital needed.

Industry Context

Many biotech companies are facing challenges in obtaining capital, with some experiencing layoffs, reductions in operations, or complete closures. TransCode's strategy has allowed them to raise capital in a difficult environment, but they still face the risk of delisting.

Comparison to Industry Standards

• Many biotech companies are struggling to maintain their stock prices above $1.00 to remain compliant with NASDAQ listing requirements, similar to TransCode Therapeutics.
• Other companies in the biotech sector, such as those developing novel cancer therapies, are also actively pursuing non-dilutive funding options like government grants and partnerships to extend their cash runway.
• The need for reverse stock splits to maintain listing compliance is a common occurrence among small-cap biotech companies facing financial challenges, as seen with companies like XOMA Corporation who have previously undertaken reverse stock splits.

Stakeholder Impact

• Shareholders face potential dilution if the reverse stock split is implemented and the company subsequently issues more shares.
• Employees' job security could be affected if the company fails to maintain its NASDAQ listing and secure additional funding.
• Patients may benefit from the company's clinical trial program if it is successful.
• Creditors face increased risk if the company's financial condition deteriorates.

Next Steps

• Shareholders need to vote on the reverse stock split proposal by April 20, 2025.
• The company needs to achieve a closing bid price of $1.00 or above by May 5, 2025, to maintain its NASDAQ listing.
• The company will continue to pursue non-dilutive funding opportunities and partnerships.
• The company will continue to advance its clinical trial program for TTX-MC138.

Key Dates

Keywords

reverse stock split, NASDAQ listing, capital raising, financing, clinical trial, TTX-MC138, TransCode Therapeutics, biotech